Skip to main content

Advertisement

SpringerLink
Log in

A clinical population pharmacokinetic/pharmacodynamic model for BIIB059, a monoclonal antibody for the treatment of systemic and cutaneous lupus erythematosus

  • Original Paper
  • Published:
Journal of Pharmacokinetics and Pharmacodynamics Aims and scope Submit manuscript

Abstract

A population pharmacokinetic/pharmacodynamic (popPK/PD) model for BIIB059 (anti-blood dendritic cell antigen 2 [anti-BDCA2]), a humanized immunoglobulin G1 monoclonal antibody currently under development for the treatment of SLE and CLE, is presented. BIIB059 binds BDCA2, a plasmacytoid dendritic cell (pDC)-specific receptor that inhibits the production of IFN-I and other inflammatory mediators when ligated. Phase 1 PK and PD data of healthy adult volunteers (HV, n = 87) and SLE subjects (n = 22) were utilized for the development of the popPK/PD model. The data included single and multiple dosing of intravenous and subcutaneous BIIB059. BDCA2 internalization (PD marker) was measured for all subjects by monitoring reduction of BDCA2 on pDC cell surface and used for development of the popPD model. A two-compartment popPK model with linear plus non-linear elimination was found to best describe BIIB059 PK. BDCA2 levels were best captured using an indirect response model with stimulation of the elimination of BDCA2. Clearance in SLE subjects was 25% higher compared to HV (6.87 vs 5.52 mL/h). Bodyweight was identified as only other covariate on clearance and central volume. The estimates of EC50 and Emax were 0.35 μg/mL and 8.92, respectively. No difference in EC50 and Emax was observed between SLE and HV. The popPK/PD model described the data accurately, as evaluated by pcVPCs and bootstrap. The presented popPK/PD model for BIIB059 provides valuable insight into the dynamics and dose–response relationship of BIIB059 for the treatment of SLE and CLE and was used to guide dose selection for the Phase 2 clinical study (NCT02847598).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Kyttaris VC (2010) Systemic lupus erythematosus: from genes to organ damage. Methods Mol Biol 662:265–283

    Article  CAS  Google Scholar 

  2. Herrmann M, Voll RE, Kalden JR (2000) Etiopathogenesis of systemic lupus erythematosus. Immunol Today 21(9):424–426

    Article  CAS  Google Scholar 

  3. Levinsky RJ, Cameron JS, Soothill JF (1977) Serum immune complexes and disease activity in lupus nephritis. Lancet 1(8011):564–567

    Article  CAS  Google Scholar 

  4. Yildirim-Toruner C, Diamond B (2011) Current and novel therapeutics in the treatment of systemic lupus erythematosus. J Allergy Clin Immunol 127(2):303–312

    Article  CAS  Google Scholar 

  5. Doria A et al (2014) Optimizing outcome in SLE: treating-to-target and definition of treatment goals. Autoimmun Rev 13(7):770–777

    Article  CAS  Google Scholar 

  6. Gladman DD et al (2003) Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol 30(9):1955–1959

    Google Scholar 

  7. Petri M et al (2014) Burden of corticosteroid use in patients with systemic lupus erythematosus: results from a Delphi panel. Lupus 23(10):1006–1013

    Article  CAS  Google Scholar 

  8. Crow MK (2010) Interferon-alpha: a therapeutic target in systemic lupus erythematosus. Rheum Dis Clin North Am 36(1):173–186

    Article  Google Scholar 

  9. Elkon KB, Santer DM (2012) Complement, interferon and lupus. Curr Opin Immunol 24(6):665–670

    Article  CAS  Google Scholar 

  10. Khamashta M et al (2016) Sifalimumab, an anti-interferon-alpha monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Ann Rheum Dis 75(11):1909–1916

    Article  CAS  Google Scholar 

  11. Furie R et al (2017) Anifrolumab, an anti-interferon-alpha receptor monoclonal antibody, moderate-to-severe systemic lupus erythematosus. Arthritis Rheumatol 69(2):376–386

    Article  CAS  Google Scholar 

  12. Siegal FP et al (1999) The nature of the principal type 1 interferon-producing cells in human blood. Science 284(5421):1835–1837

    Article  CAS  Google Scholar 

  13. Blomberg S et al (2001) Presence of cutaneous interferon-alpha producing cells in patients with systemic lupus erythematosus. Lupus 10(7):484–490

    Article  CAS  Google Scholar 

  14. Farkas L et al (2001) Plasmacytoid dendritic cells (natural interferon-alpha/beta-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am J Pathol 159(1):237–243

    Article  CAS  Google Scholar 

  15. Tomasini D et al (2010) Plasmacytoid dendritic cells: an overview of their presence and distribution in different inflammatory skin diseases, with special emphasis on Jessner's lymphocytic infiltrate of the skin and cutaneous lupus erythematosus. J Cutan Pathol 37(11):1132–1139

    Article  Google Scholar 

  16. Ghoreishi M, Vera Kellet C, Dutz JP (2012) Type 1 IFN-induced protein MxA and plasmacytoid dendritic cells in lesions of morphea. Exp Dermatol 21(6):417–419

    Article  CAS  Google Scholar 

  17. Pellerin A et al (2015) Anti-BDCA2 monoclonal antibody inhibits plasmacytoid dendritic cell activation through Fc-dependent and Fc-independent mechanisms. EMBO Mol Med 7(4):464–476

    Article  CAS  Google Scholar 

  18. Dzionek A et al (2001) BDCA-2, a novel plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen capture and is a potent inhibitor of interferon alpha/beta induction. J Exp Med 194(12):1823–1834

    Article  CAS  Google Scholar 

  19. Furie R et al (2019) Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus. J Clin Invest 129(3):1359–1371

    Article  Google Scholar 

  20. Mager DE, Jusko WJ (2001) General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn 28(6):507–532

    Article  CAS  Google Scholar 

  21. O'Hara DM et al (2011) Recommendations for the validation of flow cytometric testing during drug development: II assays. J Immunol Methods 363(2):120–134

    Article  CAS  Google Scholar 

  22. Lindbom L, Ribbing J, Jonsson EN (2004) Perl-speaks-NONMEM (PsN)–a Perl module for NONMEM related programming. Comput Methods Programs Biomed 75(2):85–94

    Article  Google Scholar 

  23. Biliouris K et al (2018) A pre-clinical quantitative model predicts the pharmacokinetics/pharmacodynamics of an anti-BDCA2 monoclonal antibody in humans. J Pharmacokinet Pharmacodyn 45(6):817–827

    Article  CAS  Google Scholar 

  24. Jonsson EN, Karlsson MO (1998) Automated covariate model building within NONMEM. Pharm Res 15(9):1463–1468

    Article  CAS  Google Scholar 

  25. Bergstrand M et al (2011) Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J 13(2):143–151

    Article  Google Scholar 

  26. Mould DR, Green B (2010) Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug development. BioDrugs 24(1):23–39

    Article  CAS  Google Scholar 

  27. Puchalski T et al (2010) Pharmacokinetic and pharmacodynamic modeling of an anti-interleukin-6 chimeric monoclonal antibody (siltuximab) in patients with metastatic renal cell carcinoma. Clin Cancer Res 16(5):1652–1661

    Article  CAS  Google Scholar 

  28. Ng CM et al (2006) Pharmacokinetics/pharmacodynamics of nondepleting anti-CD4 monoclonal antibody (TRX1) in healthy human volunteers. Pharm Res 23(1):95–103

    Article  CAS  Google Scholar 

  29. Shah DK, Betts AM (2012) Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human. J Pharmacokinet Pharmacodyn 39(1):67–86

    Article  CAS  Google Scholar 

  30. Abuqayyas L, Balthasar JP (2012) Application of PBPK modeling to predict monoclonal antibody disposition in plasma and tissues in mouse models of human colorectal cancer. J Pharmacokinet Pharmacodyn 39(6):683–710

    Article  CAS  Google Scholar 

  31. Mager DE (2006) Target-mediated drug disposition and dynamics. Biochem Pharmacol 72(1):1–10

    Article  CAS  Google Scholar 

  32. Yan X, Mager DE, Krzyzanski W (2010) Selection between Michaelis-Menten and target-mediated drug disposition pharmacokinetic models. J Pharmacokinet Pharmacodyn 37(1):25–47

    Article  CAS  Google Scholar 

  33. McBride JM et al (2012) Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study. Arthritis Rheum 64(11):3666–3676

    Article  CAS  Google Scholar 

  34. Chen P et al (2015) Pharmacokinetic and pharmacodynamic relationship of AMG 811, an anti-IFN-gamma IgG1 monoclonal antibody, in patients with systemic lupus erythematosus. Pharm Res 32(2):640–653

    Article  CAS  Google Scholar 

  35. Peletier LA, Gabrielsson J (2012) Dynamics of target-mediated drug disposition: characteristic profiles and parameter identification. J Pharmacokinet Pharmacodyn 39(5):429–451

    Article  Google Scholar 

Download references

Acknowledgements

This study was supported by Biogen. We acknowledge David Dai for his initial contribution to the concept and the analysis.

Author information

Author notes

  1. Sonja Hartmann and Konstantinos Biliouris have contributed equally to the analysis.

Authors and Affiliations

  1. Department of Pharmaceutics, Center for Pharmacometrics and Systems Pharmacology, University of Florida, Orlando, FL, USA

    Sonja Hartmann, Konstantinos Biliouris, Lawrence J. Lesko & Mirjam N. Trame

  2. Biogen Inc., 225 Binney Street, Cambridge, MA, 02142, USA

    Himanshu Naik, Dania Rabah, Chase Shen & Ivan A. Nestorov

  3. Immunologix Laboratories, Tampa, FL, USA

    Lauren Stevenson

Authors
  1. Sonja Hartmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Konstantinos Biliouris
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Himanshu Naik
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dania Rabah
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Lauren Stevenson
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Chase Shen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ivan A. Nestorov
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Lawrence J. Lesko
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Mirjam N. Trame
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Himanshu Naik.

Ethics declarations

Conflict of interest

HN, LS, CS, DR, and IAN were employed by Biogen when this work was performed. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the views or position of any of their employers.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hartmann, S., Biliouris, K., Naik, H. et al. A clinical population pharmacokinetic/pharmacodynamic model for BIIB059, a monoclonal antibody for the treatment of systemic and cutaneous lupus erythematosus. J Pharmacokinet Pharmacodyn 47, 255–266 (2020). https://doi.org/10.1007/s10928-020-09688-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10928-020-09688-y

Keywords

Search

Navigation